Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | BRAF | P15056 | 3/20 | 0.59 |
| ▸ | ABL1 | P00519 | 4/20 | 0.57 |
| ▸ | RET | P07949 | 11/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.55 |
| ▸ | BCR | P11274 | 2/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15859875 | 0.95 | ABL1 (0.56) | EGFRBRAFABL1RETSRC | |
| SCHEMBL15847641 | 0.91 | EGFR (0.54) | EGFRBRAFABL1RETSRC | |
| SCHEMBL15860119 | 0.89 | MAP3K20 (0.56) | EGFRBRAFABL1RETSRC | |
| SCHEMBL15859839 | 0.88 | EGFR (0.58) | EGFRBRAFABL1RETMAP3K20 | |
| SCHEMBL17321174 | 0.88 | ABL1 (0.56) | EGFRBRAFABL1RETSRC | |
| SCHEMBL15859903 | 0.88 | EGFR (0.60) | EGFRBRAFABL1SRCBCR | |
| SCHEMBL17321133 | 0.87 | ABL1 (0.56) | EGFRBRAFABL1RETSRC | |
| SCHEMBL15859881 | 0.87 | BRAF (0.58) | EGFRBRAFCSF1R | |
| SCHEMBL15859948 | 0.86 | EGFR (0.56) | EGFRBRAFABL1RETMAP3K20 | |
| SCHEMBL15860121 | 0.85 | MAP3K20 (0.59) | EGFRBRAFABL1RETMAP3K20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493455-B2 | Azaindole derivatives as inhibitors of protein kinases | ORIBASE PHARMA (FR) | 2016-11-15 | — | — | US | disclosed |
| US-9493455-B2 | Azaindole derivatives as inhibitors of protein kinases | ORIBASE PHARMA (FR) | 2016-11-15 | — | — | US | disclosed |
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| EP-2938613-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | OriBase Pharma (FR) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014102378-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2014-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K3, MAP3K20 | EGFR 1624/4885BRAF 65/4885ABL1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.